Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.32 -0.9%	$2.36	$1.29 ▼ $7.85	$256.73M	1.3	1.47 million shs	1.38 million shs
DBVT DBV Technologies	$10.00 +3.0%	$9.65	$2.20 ▼ $12.78	$265.96M	-0.59	191,543 shs	55,371 shs
PYXS Pyxis Oncology	$1.13 -3.4%	$1.20	$0.83 ▼ $5.39	$72.48M	1.13	720,924 shs	194,020 shs
SGMT Sagimet Biosciences	$9.41 -1.5%	$6.43	$1.73 ▼ $10.43	$292.95M	3.35	1.09 million shs	487,598 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-0.85%	-10.08%	-0.85%	+58.90%	-60.48%
DBVT DBV Technologies	+2.99%	-7.41%	+1.52%	+25.31%	+150.00%
PYXS Pyxis Oncology	-3.42%	-2.59%	-0.88%	+17.31%	-65.44%
SGMT Sagimet Biosciences	-1.47%	-0.63%	+33.66%	+325.79%	+176.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.2271 of 5 stars	3.5	2.0	0.8	2.5	0.6
DBVT DBV Technologies	3.9523 of 5 stars	4.4	5.0	2.0	2.5	0.6
PYXS Pyxis Oncology	2.4489 of 5 stars	3.4	3.0	2.4	0.8	0.6
SGMT Sagimet Biosciences	1.9008 of 5 stars	3.5	3.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	3.00	Buy	$12.50	438.79% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	47.50% Upside
PYXS Pyxis Oncology	2.80	Moderate Buy	$9.00	696.46% Upside
SGMT Sagimet Biosciences	3.00	Buy	$26.60	182.68% Upside

Current Analyst Ratings Breakdown

Latest PYXS, SGMT, DBVT, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/14/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $14.00
5/13/2025	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $11.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$2.75 per share	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$1.42 per share	N/A
PYXS Pyxis Oncology	$16.15M	4.33	N/A	N/A	$2.03 per share	0.56
SGMT Sagimet Biosciences	$2M	144.30	N/A	N/A	$5.08 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.18	N/A	N/A	N/A	N/A	-54.45%	-46.56%	8/11/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
PYXS Pyxis Oncology	-$77.33M	-$1.59	N/A	N/A	N/A	N/A	-57.49%	-45.17%	8/13/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.76	N/A	N/A	N/A	N/A	-35.21%	-34.09%	8/13/2025 (Estimated)

Latest PYXS, SGMT, DBVT, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PYXS Pyxis Oncology	-$0.36	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.57	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ANNX Annexon	-$0.36	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/15/2025	Q1 2025	PYXS Pyxis Oncology	-$0.29	-$0.35	-$0.06	-$0.35	N/A	N/A
5/12/2025	Q1 2025	ANNX Annexon	-$0.30	-$0.37	-$0.07	-$0.37	N/A	N/A
5/8/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	-$0.56	+$0.23	-$0.56	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	7.99	7.99
DBVT DBV Technologies	N/A	0.72	0.72
PYXS Pyxis Oncology	N/A	7.75	7.75
SGMT Sagimet Biosciences	N/A	20.34	20.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
DBVT DBV Technologies	71.74%
PYXS Pyxis Oncology	39.09%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	11.87%
DBVT DBV Technologies	1.44%
PYXS Pyxis Oncology	10.60%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.71 million	96.69 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
PYXS Pyxis Oncology	60	61.95 million	55.38 million	Optionable
SGMT Sagimet Biosciences	8	30.67 million	26.17 million	Optionable

PYXS, SGMT, DBVT, and ANNX Headlines

Recent News About These Companies

We Think Sagimet Biosciences (NASDAQ:SGMT) Can Afford To Drive Business Growth

July 16 at 5:08 PM | finance.yahoo.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by Analysts

July 1, 2025 | marketbeat.com

SGMT Sagimet Biosciences Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Sagimet Biosciences Inc News (SGMT) - Investing.com

June 27, 2025 | investing.com

Sagimet Biosciences Inc. (SGMT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Sagimet Biosciences Inc.

June 14, 2025 | wsj.com

Sagimet Biosciences updates executive compensation

June 12, 2025 | investing.com

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

June 11, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...

June 11, 2025 | morningstar.comM

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know

June 9, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

June 9, 2025 | globenewswire.com

Sagimet Biosciences Analyst Ratings

June 5, 2025 | benzinga.com

Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment

June 4, 2025 | marketwatch.com

Sagimet Biosciences shares soar on positive acne treatment trial results

June 4, 2025 | ca.investing.com

Sagimet partner Ascletis announces significant Phase III acne data

June 4, 2025 | thepharmaletter.comT

Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results

June 4, 2025 | msn.com

Sagimet climbs as acne therapy hits main goals in late-stage trial in China

June 4, 2025 | msn.com

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

June 4, 2025 | aol.comA

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

June 4, 2025 | seekingalpha.com

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

June 4, 2025 | globenewswire.com

Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, SGMT, DBVT, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$2.32 -0.02 (-0.85%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.31 -0.01 (-0.65%)

As of 07/18/2025 07:30 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

DBV Technologies NASDAQ:DBVT

$10.00 +0.29 (+2.99%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$10.30 +0.30 (+3.00%)

As of 07/18/2025 07:20 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Pyxis Oncology NASDAQ:PYXS

$1.13 -0.04 (-3.42%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.14 +0.01 (+0.97%)

As of 07/18/2025 07:34 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Sagimet Biosciences NASDAQ:SGMT

$9.41 -0.14 (-1.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$9.35 -0.06 (-0.64%)

As of 07/18/2025 05:44 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time